Standard BioTools Inc. (LAB)

US — Healthcare Sector

Peers: STRRP GTH BDSX NDRA OLK FONR MDXH NOTV BNR SERA LMDX STIM DRIO

Automate Your Wheel Strategy on LAB

With Tiblio's Option Bot, you can configure your own wheel strategy including LAB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol LAB
Rev/Share 0.4486
Book/Share 1.2019
PB 0.8269
Debt/Equity 0.0694
CurrentRatio 6.1174
ROIC -0.2639

MktCap 377505086.0
FreeCF/Share -0.3276
PFCF -3.0471
PE -2.8316
Debt/Assets 0.0544
DivYield 0
ROE -0.2757

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 1
P/B Score 4
D/E Score 3

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Downgrade	LAB	KeyBanc Capital Markets	Overweight	Sector Weight	--	--	Feb. 27, 2025

News

Standard BioTools Inc. (LAB) Q1 2025 Earnings Conference Call Transcript

LAB
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral

Standard BioTools Inc. (NASDAQ:LAB ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants John Graziano - VP of IR Michael Egholm - President & CEO Alex Kim - CFO Conference Call Participants Kyle Boucher - TD Cowen Matt Stanton - Jefferies Paul Knight - KeyBanc Operator Good day and welcome to the Standard BioTools, Inc., First Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.

image for news Standard BioTools Inc. (LAB) Q1 2025 Earnings Conference Call Transcript

Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates

LAB
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral

Standard BioTools (LAB) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.23 per share a year ago.

image for news Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates

Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

LAB
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.

image for news Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

Standard BioTools to Participate in Upcoming Investor Conferences

LAB
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences:

image for news Standard BioTools to Participate in Upcoming Investor Conferences

Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript

LAB
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral

Standard BioTools Inc. (NASDAQ:LAB ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Michael Egholm - President & CEO Alex Kim - Chief Operating Officer & Interim-CFO Conference Call Participants Matt Stanton - Jefferies Kyle Boucher - TD Cowen Paul Knight - KeyBanc Operator Good day, everyone, and welcome to Standard BioTools' Fourth Quarter and Full Year 2024 Financial Results Conference Call. As a reminder, this conference is being recorded.

image for news Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript

Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

LAB
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2024.

image for news Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

LAB
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close.

image for news Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

About Standard BioTools Inc. (LAB)

IPO Date 2011-02-10
Website https://www.fluidigm.com
Industry Medical - Diagnostics & Research
CEO Dr. Michael Egholm Ph.D.
Employees 814

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.